Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mironcol Diagnostics Ltd. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action, which is the only active matter in the company's prosecution pipeline. This action is assigned to 1 distinct examiner, YU, TIAN NMN, who is also the busiest examiner for the company. The data indicates that YU, TIAN NMN is handling 1 busiest examiner pending action, covering the entire current workload.
The prosecution is conducted within 1 distinct art unit, reflecting a narrow administrative and technical focus for the company's biotechnological filings. For a practitioner, this concentration means that the outcome of the 1 pending office action rests solely with YU, TIAN NMN. There is no examiner or art unit diversity to provide alternative perspectives or to spread the risk of a negative examination. The 1 distinct art unit and 1 distinct examiner represent the total environment for the company's current patent review process. The pending office action is the only case currently being evaluated within this specific technical and administrative framework.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, TIAN NMN | 1 | 55.1% | +20.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18536108 | CANCER DETECTION METHOD, KIT, AND SYSTEM | YU, TIAN NMN | 29d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18536108 | CANCER DETECTION METHOD, KIT, AND SYSTEM | YU, TIAN NMN | 29d |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18536108 | CANCER DETECTION METHOD, KIT, AND SYSTEM | YU, TIAN NMN | 1681 | §101§102§112 | Non-Final OA | 29d | Pending | Dec 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial